Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C Virus

Journal of Medical Virology

Volumn 82, Issue 3, 2010, Pages 390-395

  Arase, Yasuji ^a,b   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Akuta, Norio ^a   Kobayashi, Masahiro ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Hirakawa, Miharu ^a   Ikeda, Kenji ^a   Hsieh, Shiun Dong ^a   Oomoto, Yuki ^a   Amakawa, Kazuhisa ^a   Kato, Hisahito ^a   Kazawa, Tamae ^a   Tsuji, Hiroshi ^a   Kobayashi, Tetsuro ^b   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Bone fracture; Chronic hepatitis C; Interferon; Osteoporosis

Indexed keywords

ALBUMIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; INTERFERON;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FRAGILITY FRACTURE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; RISK REDUCTION;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; FRACTURES, BONE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; LIVER; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RETROSPECTIVE STUDIES; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 75449098534     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21691     Document Type: Article

References (21)

1. Abraham AK, Ramanathan M, Weinstock-Guttman B, Mager DE. 2009. Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol 77:1757-1762.
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. 1992. The natural history of community acquired hepatitis C in the United States. N Engl J Med 327:1899-1905.
3. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Ikeda K, Kumada H. 2008. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J Med Virol 80:1302-1307.
4. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H. 2009a. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49:739-744.
5. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H. 2009b. The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2. Intern Med 48:1337-1342.
6. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading, and staging. Hepatology 19:1513-1520.
7. Gumber SC, Chopra S. 1995. Hepatitis C: A multifaceted disease - Review of extra hepatic manifestations. Ann Intern Med 123:615-620.
8. Harrington DP, Fleming TR. 1983. A class of rank test procedures for censored survival data. Biomedica 62:553-566.
9. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M. 1993. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18:47-53.
10. Katamura Y, Suzuki F, Akuta N, Sezaki H, Yatsuji H, Nomura N, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Saito S, Arase Y, Ikeda K, Kobayashi M, Kumada H. 2008. Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load. Intern Med 47:1827-1834.
11. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Kumada H. 2007. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 120:1034-1041.
12. Kiyosawa K, Furuta S. 1991. Review of hepatitis C in Japan. J Gastroenterol Hepatol 6:383-391.
13. Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Jackson PD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut GH III. 1997. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med 103:468-476.
14. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A. 2005. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3:705-713.
15. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben Yahia MB, André C, Voisin MC, Intrator L, Zafrani ES, Duval J, Dhumeaux D. 1995. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 122:169-173.
16. Rouillard S, Lane NE. 2001. Hepatic osteodystrophy. Hepatology 33:301-307.
17. Shiomi S, Nishiguchi S, Kurooka H, Tamori A, Habu D, Takeda T, Ochi H. 2002. Cyclical etidronate for treatment of osteopenia in patients with cirrhosis of the liver. Hepatol Res 22:102-106.
18. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T. 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416:744-749.
19. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H. 1993. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801.
20. Tsuneoka K, Tameda Y, Takase K, Nakano T. 1996. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 31:669-678.
21. Yoshida T, Muto Y, Moriwaki H, Yamato M. 1989. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterology 24:692-698.